MDGL
Madrigal Pharmaceuticals Inc
$537.52
▲ 2.5%Updated Today 11:10 AM ET
MDGL at a glance — five pillars scored 0–100 from real filed financials.
Overall: Unrated · 0/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
Market Cap
$0.00
P/E
—
Forward P/E (est.)
—
ROE
—
Revenue Growth
—
EPS Growth
—
Profit Margin
—
FCF Yield
—
Debt / Equity
—
ROIC
-27.0%
Interest Coverage
—
Current Ratio
3.2x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
0/100
Madrigal Pharmaceuticals Inc (MDGL) is a small-cap company in the Biotechnology industry, part of the Health Care sector of the S&P 500.
In its latest reported year it generated about $958.40M in revenue and posted a net loss of $288.28M.
Our model rates MDGL Unrated (0/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Gross Margin
—
Operating Margin
-31.3%
Net Margin
-30.1%
ROE
—
Total Debt
$340.79M
Net Debt
$48.07M
Net Debt / EBITDA
—
Debt / Equity
—
Leverage: debt-to-equity is n/a, with a current ratio of 3.2x. Detailed balance-sheet leverage is limited for this name. It carries roughly $340.79M of total debt against $292.73M of cash.
Operating CF
-$189.55M
Free Cash Flow
-$190.02M
FCF Margin
-19.8%
In the latest year Madrigal Pharmaceuticals Inc produced about -$189.55M of operating cash flow but negative free cash flow as it invested heavily. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
—
P/S
—
P/B
—
EV / EBITDA
—
MDGL trades at n/a trailing earnings. With no positive trailing earnings, value it on sales, cash flow, or growth rather than P/E.
Where MDGL sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How MDGL stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), MDGL ranks #216 of 324 by our overall rating.
P/E vs sector
—
median 27.3x
ROE vs sector
—
median 14.1%
Growth vs sector
—
median 7.6%
Sector rank
#216
of 324 by rating
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $537.52 today · expected CAGR -47% – -42%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $1.04B | $1.12B | $1.21B | $1.30B | $1.41B |
| Net income | $31.05M | $33.54M | $36.22M | $39.12M | $42.25M |
| EPS | $1.34 | $1.45 | $1.57 | $1.69 | $1.83 |
| Share price (low) | $16.13 | $17.42 | $18.81 | $20.32 | $21.94 |
| Share price (high) | $26.88 | $29.03 | $31.35 | $33.86 | $36.57 |
| CAGR (low–high) | -97% / -95% | -82% / -77% | -67% / -61% | -56% / -50% | -47% / -42% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for MDGL:
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against MDGL:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Madrigal Pharmaceuticals Inc is a small-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at n/a earnings, which our model scores Unrated (0/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Latest SEC Filings
MDGL's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
MDGL — frequently asked questions
Is MDGL a good stock to buy?
We don't give buy or sell advice. Review Madrigal Pharmaceuticals Inc's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.
Where does MDGL's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Madrigal Pharmaceuticals Inc's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for MDGL calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this MDGL analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell MDGL. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.